Shanghai Pharmaceuticals' Cefazolin Sodium Injection Passes Bioequivalence Assessment

Stock News03-17

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinya Pharmaceutical Co., Ltd., has received a Supplemental Application Approval Notice from the National Medical Products Administration for Cefazolin Sodium for Injection. The drug has passed the consistency evaluation for generic drug quality and efficacy. Cefazolin Sodium for Injection is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infectious endocarditis, hepatobiliary system infections, reproductive system infections, and for perioperative prevention of infection caused by susceptible bacteria.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128589770?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 15:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128589770","market":"sh","top_or_hot":-1,"title":"Shanghai Pharmaceuticals' Cefazolin Sodium Injection Passes Bioequivalence Assessment","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinya Pharmaceutical Co., Ltd., has received a Supplemental Application Approval Notice from the National Medical Products Administration for Cefazolin Sodium for Injection. The drug has passed the consistency evaluation for generic drug quality and efficacy. Cefazolin Sodium for Injection is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infectious endocarditis, hepatobiliary system infections, reproductive system infections, and for perioperative prevention of infection caused by susceptible bacteria.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals' Cefazolin Sodium Injection Passes Bioequivalence Assessment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals' Cefazolin Sodium Injection Passes Bioequivalence Assessment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-17 15:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinya Pharmaceutical Co., Ltd., has received a Supplemental Application Approval Notice from the National Medical Products Administration for Cefazolin Sodium for Injection. The drug has passed the consistency evaluation for generic drug quality and efficacy. Cefazolin Sodium for Injection is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infectious endocarditis, hepatobiliary system infections, reproductive system infections, and for perioperative prevention of infection caused by susceptible bacteria.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0209","symbol_name":"零售","start_time":0,"source_url":"","article_id":"1128589770","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128589770","pubTimestamp":1773733242,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinya Pharmaceutical Co., Ltd., has received a Supplemental Application Approval Notice from...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0209":"零售","BK0097":"医药电商","02607":"上海医药","BK1197":"保健护理产品经销商","BK0196":"行业龙头","BK0028":"国家队","BK0183":"MSCI概念","BK0175":"白马股","BK0012":"证金概念","BK0188":"融资融券","BK0184":"上海国资改革","BK0020":"浦东新区","BK0099":"上海本地重组","BK0187":"一线龙头"},"translate_title":"上海医药头孢唑林钠注射液通过生物等效性评价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinya Pharmaceutical Co., Ltd., has received a Supplemental Application Approval Notice from the National Medical Products Administration for Cefazolin Sodium for Injection. The drug has passed the consistency evaluation for generic drug quality and efficacy. Cefazolin Sodium for Injection is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infectious endocarditis, hepatobiliary system infections, reproductive system infections, and for perioperative prevention of infection caused by susceptible bacteria.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128589770","isCrawlerRequest":true}